Using FDG-PET to Measure Early Treatment Response in Head and Neck Squamous Cell Carcinoma: Quantifying Intrinsic Variability in Order to Understand Treatment-Induced Change

J.K. Hoang; S.K. Das; K.R. Choudhury; D.S. Yoo; D.M. Brizel

doi:10.3174/ajnr.A3412

REFERENCES

1.↵
1. Higgins KA,
2. Hoang JK,
3. Roach MC,
4. et al
. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value. Int J Radiat Oncol Biol Phys 2012;82:548–53
CrossRef PubMed
2.↵
1. Kapoor V,
2. Fukui MB,
3. McCook BM
. Role of 18FFDG PET/CT in the treatment of head and neck cancers: principles, technique, normal distribution, and initial staging. AJR Am J Roentgenol 2005;184:579–87
CrossRef PubMed
3.↵
1. Porceddu SV,
2. Pryor DI,
3. Burmeister E,
4. et al
. Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. Head Neck 2011;33:1675–82
CrossRef PubMed
4.↵
1. Yoo DS,
2. Kirkpatrick JP,
3. Craciunescu O,
4. et al
. Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. Clin Cancer Res 2012;18:1404–14
Abstract/FREE Full Text
5.↵
1. van Heijl M,
2. Omloo JM,
3. van Berge Henegouwen MI,
4. et al
. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg 2011;253:56–63
CrossRef PubMed
6.↵
1. Markova J,
2. Kobe C,
3. Skopalova M,
4. et al
. FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value. Ann Oncol 2009;20:1270–74
Abstract/FREE Full Text
7.↵
1. Benz MR,
2. Czernin J,
3. Allen-Auerbach MS,
4. et al
. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res 2009;15:2856–63
Abstract/FREE Full Text
8.↵
1. Hoekstra CJ,
2. Stroobants SG,
3. Smit EF,
4. et al
. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005;23:8362–70
Abstract/FREE Full Text
9.↵
1. Weber WA,
2. Ziegler SI,
3. Thodtmann R,
4. et al
. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999;40:1771–77
Abstract/FREE Full Text
10.↵
1. Frings V,
2. de Langen AJ,
3. Smit EF,
4. et al
. Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer. J Nucl Med 2010;51:1870–77
Abstract/FREE Full Text
11.↵
1. Velasquez LM,
2. Boellaard R,
3. Kollia G,
4. et al
. Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies. J Nucl Med 2009;50:1646–54
Abstract/FREE Full Text
12.↵
1. Nahmias C,
2. Wahl LM
. Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors. J Nucl Med 2008;49:1804–08
Abstract/FREE Full Text
13.↵
1. Chu KP,
2. Murphy JD,
3. La TH,
4. et al
. Prognostic value of metabolic tumor volume and velocity in predicting head-and-neck cancer outcomes. Int J Radiat Oncol Biol Phys 2012;83:1521–27
CrossRef PubMed
14.↵
1. Wahl RL,
2. Jacene H,
3. Kasamon Y,
4. et al
. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(suppl 1):122S–50S
Abstract/FREE Full Text
15.↵
1. Bland JM,
2. Altman DG
. Measuring agreement in method comparison studies. Stat Methods Med Res 1999;8:135–60
Abstract/FREE Full Text
16.↵
1. Geets X,
2. Tomsej M,
3. Lee JA,
4. et al
. Adaptive biological image-guided IMRT with anatomic and functional imaging in pharyngo-laryngeal tumors: impact on target volume delineation and dose distribution using helical tomotherapy. Radiother Oncol 2007;85:105–15
CrossRef PubMed Web of Science

In this issue

Download PDF

Email Article

Citation Tools

Purchase

Cited By...

More in this TOC Section

Show more HEAD & NECK

[1] 1.↵
Higgins KA,
Hoang JK,
Roach MC,
et al
. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value. Int J Radiat Oncol Biol Phys 2012;82:548–53
CrossRef PubMed

[2] Higgins KA,

[3] Hoang JK,

[4] Roach MC,

[5] et al

[6] 2.↵
Kapoor V,
Fukui MB,
McCook BM
. Role of 18FFDG PET/CT in the treatment of head and neck cancers: principles, technique, normal distribution, and initial staging. AJR Am J Roentgenol 2005;184:579–87
CrossRef PubMed

[7] Kapoor V,

[8] Fukui MB,

[9] McCook BM

[10] 3.↵
Porceddu SV,
Pryor DI,
Burmeister E,
et al
. Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. Head Neck 2011;33:1675–82
CrossRef PubMed

[11] Porceddu SV,

[12] Pryor DI,

[13] Burmeister E,

[14] et al

[15] 4.↵
Yoo DS,
Kirkpatrick JP,
Craciunescu O,
et al
. Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. Clin Cancer Res 2012;18:1404–14
Abstract/FREE Full Text

[16] Yoo DS,

[17] Kirkpatrick JP,

[18] Craciunescu O,

[19] et al

[20] 5.↵
van Heijl M,
Omloo JM,
van Berge Henegouwen MI,
et al
. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg 2011;253:56–63
CrossRef PubMed

[21] van Heijl M,

[22] Omloo JM,

[23] van Berge Henegouwen MI,

[24] et al

[25] 6.↵
Markova J,
Kobe C,
Skopalova M,
et al
. FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value. Ann Oncol 2009;20:1270–74
Abstract/FREE Full Text

[26] Markova J,

[27] Kobe C,

[28] Skopalova M,

[29] et al

[30] 7.↵
Benz MR,
Czernin J,
Allen-Auerbach MS,
et al
. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res 2009;15:2856–63
Abstract/FREE Full Text

[31] Benz MR,

[32] Czernin J,

[33] Allen-Auerbach MS,

[34] et al

[35] 8.↵
Hoekstra CJ,
Stroobants SG,
Smit EF,
et al
. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005;23:8362–70
Abstract/FREE Full Text

[36] Hoekstra CJ,

[37] Stroobants SG,

[38] Smit EF,

[39] et al

[40] 9.↵
Weber WA,
Ziegler SI,
Thodtmann R,
et al
. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999;40:1771–77
Abstract/FREE Full Text

[41] Weber WA,

[42] Ziegler SI,

[43] Thodtmann R,

[44] et al

[45] 10.↵
Frings V,
de Langen AJ,
Smit EF,
et al
. Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer. J Nucl Med 2010;51:1870–77
Abstract/FREE Full Text

[46] Frings V,

[47] de Langen AJ,

[48] Smit EF,

[49] et al

[50] 11.↵
Velasquez LM,
Boellaard R,
Kollia G,
et al
. Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies. J Nucl Med 2009;50:1646–54
Abstract/FREE Full Text

[51] Velasquez LM,

[52] Boellaard R,

[53] Kollia G,

[54] et al

[55] 12.↵
Nahmias C,
Wahl LM
. Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors. J Nucl Med 2008;49:1804–08
Abstract/FREE Full Text

[56] Nahmias C,

[57] Wahl LM

[58] 13.↵
Chu KP,
Murphy JD,
La TH,
et al
. Prognostic value of metabolic tumor volume and velocity in predicting head-and-neck cancer outcomes. Int J Radiat Oncol Biol Phys 2012;83:1521–27
CrossRef PubMed

[59] Chu KP,

[60] Murphy JD,

[61] La TH,

[62] et al

[63] 14.↵
Wahl RL,
Jacene H,
Kasamon Y,
et al
. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(suppl 1):122S–50S
Abstract/FREE Full Text

[64] Wahl RL,

[65] Jacene H,

[66] Kasamon Y,

[67] et al

[68] 15.↵
Bland JM,
Altman DG
. Measuring agreement in method comparison studies. Stat Methods Med Res 1999;8:135–60
Abstract/FREE Full Text

[69] Bland JM,

[70] Altman DG

[71] 16.↵
Geets X,
Tomsej M,
Lee JA,
et al
. Adaptive biological image-guided IMRT with anatomic and functional imaging in pharyngo-laryngeal tumors: impact on target volume delineation and dose distribution using helical tomotherapy. Radiother Oncol 2007;85:105–15
CrossRef PubMed Web of Science

[72] Geets X,

[73] Tomsej M,

[74] Lee JA,

[75] et al

Main menu

User menu

Search

American Journal of Neuroradiology

Using FDG-PET to Measure Early Treatment Response in Head and Neck Squamous Cell Carcinoma: Quantifying Intrinsic Variability in Order to Understand Treatment-Induced Change

REFERENCES

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

News and Updates

Resources

Opportunities

American Society of Neuroradiology

Main menu

User menu

Search

Using FDG-PET to Measure Early Treatment Response in Head and Neck Squamous Cell Carcinoma: Quantifying Intrinsic Variability in Order to Understand Treatment-Induced Change

REFERENCES

In this issue

Citation Manager Formats

Jump to section

Related Articles

Cited By...

More in this TOC Section

Similar Articles

News and Updates

Resources

Opportunities

American Society of Neuroradiology